Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.
Tsukamoto S, Kobayashi K, Toyoda M, Hatori N, Kanaoka T, Wakui H, Sakai H, Furuki T, Chin K, Ito S, Suzuki D, Umezono T, Aoyama T, Nakajima S, Hishiki T, Hatori Y, Hayashi M, Shimura H, Minagawa F, Mokubo A, Takihata M, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Tsukamoto S, et al. Among authors: mokubo a. Hypertens Res. 2024 Mar;47(3):628-638. doi: 10.1038/s41440-023-01464-y. Epub 2023 Oct 17. Hypertens Res. 2024. PMID: 37848562
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kobayashi K, Toyoda M, Kimura M, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Sato K, Miyakawa M. Kobayashi K, et al. Among authors: mokubo a. Diab Vasc Dis Res. 2019 Jan;16(1):103-107. doi: 10.1177/1479164118802759. Epub 2018 Oct 4. Diab Vasc Dis Res. 2019. PMID: 30284913 Free article.
Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring.
Kobayashi K, Toyoda M, Kimura M, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Sato K, Miyakawa M. Kobayashi K, et al. Among authors: mokubo a. Clin Exp Hypertens. 2019;41(7):637-644. doi: 10.1080/10641963.2018.1529778. Epub 2018 Oct 29. Clin Exp Hypertens. 2019. PMID: 30373408
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
Kobayashi K, Toyoda M, Kaneyama N, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Miyakawa M. Kobayashi K, et al. Among authors: mokubo a. J Diabetes Res. 2019 Nov 3;2019:9415313. doi: 10.1155/2019/9415313. eCollection 2019. J Diabetes Res. 2019. PMID: 31781668 Free PMC article.
Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?
Kawata T, Kanamori A, Kubota A, Maeda H, Amamiya H, Takai M, Kaneshige H, Minagawa F, Iemitsu K, Kaneshiro M, Ishikawa M, Takeda H, Takuma T, Mokubo A, Machimura H, Obana M, Miyakawa M, Naka Y, Suzuki D, Terauchi Y, Toyoda M, Tanaka Y, Matsuba I. Kawata T, et al. Among authors: mokubo a. J Clin Med Res. 2014 Apr;6(2):138-44. doi: 10.14740/jocmr1719w. Epub 2014 Feb 6. J Clin Med Res. 2014. PMID: 24578756 Free PMC article.
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Kawata T, et al. Among authors: mokubo a. J Clin Med Res. 2017 Jul;9(7):586-595. doi: 10.14740/jocmr3038w. Epub 2017 May 22. J Clin Med Res. 2017. PMID: 28611859 Free PMC article.
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Matsuba I, Kawata T, Iemitsu K, Asakura T, Amemiya H, Ishikawa M, Ito S, Kaneshiro M, Kanamori A, Kubota A, Shinoda K, Takai M, Takuma T, Takihata M, Takeda H, Tanaka K, Matsuzawa Y, Machimura H, Minagawa F, Minami N, Mokubo A, Miyakawa M, Terauchi Y, Tanaka Y. Matsuba I, et al. Among authors: mokubo a. J Diabetes Investig. 2020 Sep;11(5):1248-1257. doi: 10.1111/jdi.13248. Epub 2020 Apr 25. J Diabetes Investig. 2020. PMID: 32149469 Free PMC article.
Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.
Matsuba I, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Kanamori A. Matsuba I, et al. Among authors: mokubo a. Diabetes Obes Metab. 2021 Dec;23(12):2614-2622. doi: 10.1111/dom.14508. Epub 2021 Aug 12. Diabetes Obes Metab. 2021. PMID: 34338409
Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iizuka T, et al. Among authors: mokubo a. J Clin Med Res. 2016 Feb;8(2):116-25. doi: 10.14740/jocmr2417w. Epub 2015 Dec 28. J Clin Med Res. 2016. PMID: 26767080 Free PMC article.
Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
Iemitsu K, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Obana M, Sasai N, Kaneshige H, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iemitsu K, et al. Among authors: mokubo a. J Clin Med Res. 2016 May;8(5):373-8. doi: 10.14740/jocmr2492w. Epub 2016 Mar 20. J Clin Med Res. 2016. PMID: 27081422 Free PMC article.
35 results